Genmab A GMAB
NASDAQ GMAB
$54.07 -1.74 (-3.12%)
At close: Nov 10, 2026 · 4:00 PM EST

Genmab A (GMAB) EBIT Margin (2023 - 2026)

Updated

Genmab A (GMAB) reported EBIT Margin of 32.47% for the quarter ended Jun 30, 2026, up 12.38 percentage points from the prior quarter.

Analysis

Genmab A (GMAB) EBIT Margin (2023 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Genmab A's EBIT Margin came in at 34.37%; for the year ended Dec 31, 2025, it came in at 28.63%, down 2.51 percentage points from the prior year.

  • By year, EBIT Margin came in at 31.14% in the year ended Dec 31, 2024 (-1.16 pp) and 32.30% in the year ended Dec 31, 2023.
  • Five-year quarterly EBIT Margin spans a low of 20.09% in the quarter ended Mar 31, 2026 and a high of 44.91% in the quarter ended Sep 30, 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 52.42%
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 24.35%
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 36.01%
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 30.89%
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 32.97%
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn 20.57%
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 35.79%
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 41.71%
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 32.98%
10 Genmab A 3.52 Bn -5.55 Bn 1.07 Bn 32.47%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 36.31%
Jun 30, 2026 32.47%
Mar 31, 2026 20.09%
Sep 30, 2025 44.91%
Jun 30, 2025 38.92%
Mar 31, 2025 26.29%
Sep 30, 2024 37.99%
Jun 30, 2024 30.30%
Mar 31, 2024 19.24%
Sep 30, 2023 35.76%
API Access

Genmab A EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=GMAB&period=max&api_key=YOUR_API_KEY